Skip to main content
Erschienen in: European Radiology 8/2023

30.03.2023 | Magnetic Resonance

Prediction of platinum resistance for advanced high-grade serous ovarian carcinoma using MRI-based radiomics nomogram

verfasst von: Haiming Li, Songqi Cai, Lin Deng, Zebin Xiao, Qinhao Guo, Jinwei Qiang, Jing Gong, Yajia Gu, Zaiyi Liu

Erschienen in: European Radiology | Ausgabe 8/2023

Einloggen, um Zugang zu erhalten

Abstract

Objective

This study aimed to explore the value of a radiomics nomogram to identify platinum resistance and predict the progression-free survival (PFS) of patients with advanced high-grade serous ovarian carcinoma (HGSOC).

Materials and methods

In this multicenter retrospective study, 301 patients with advanced HGSOC underwent radiomics features extraction from the whole primary tumor on contrast-enhanced T1WI and T2WI. The radiomics features were selected by the support vector machine–based recursive feature elimination method, and then the radiomics signature was generated. Furthermore, a radiomics nomogram was developed using the radiomics signature and clinical characteristics by multivariable logistic regression. The predictive performance was evaluated using receiver operating characteristic analysis. The net reclassification index (NRI), integrated discrimination improvement (IDI), and decision curve analysis (DCA) were used to compare the clinical utility and benefits of different models.

Results

Five features significantly correlated with platinum resistance were selected to construct the radiomics model. The radiomics nomogram, combining radiomics signatures with three clinical characteristics (FIGO stage, CA-125, and residual tumor), had a higher area under the curve (AUC) compared with the clinical model alone (AUC: 0.799 vs 0.747), with positive NRI and IDI. The net benefit of the radiomics nomogram is typically higher than clinical-only and radiomics-only models. Kaplan–Meier survival analysis showed that the radiomics nomogram–defined high-risk groups had shorter PFS compared with the low-risk groups in patients with advanced HGSOC.

Conclusions

The radiomics nomogram can identify platinum resistance and predict PFS. It helps make the personalized management of advanced HGSOC.

Key Points

The radiomics-based approach has the potential to identify platinum resistance and can help make the personalized management of advanced HGSOC.
The radiomics–clinical nomogram showed improved performance compared with either of them alone for predicting platinum-resistant HGSOC.
The proposed nomogram performed well in predicting the PFS time of patients with low-risk and high-risk HGSOC in both training and testing cohorts.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249CrossRefPubMed Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249CrossRefPubMed
3.
Zurück zum Zitat US Preventive Services Task Force, Grossman DC, Curry SJ et al (2018) Screening for ovarian cancer: US Preventive Services Task Force Recommendation Statement. JAMA 319:588–594CrossRef US Preventive Services Task Force, Grossman DC, Curry SJ et al (2018) Screening for ovarian cancer: US Preventive Services Task Force Recommendation Statement. JAMA 319:588–594CrossRef
4.
Zurück zum Zitat McMullen M, Madariaga A, Lheureux S (2021) New approaches for targeting platinum-resistant ovarian cancer. Semin Cancer Biol 77:167–181CrossRefPubMed McMullen M, Madariaga A, Lheureux S (2021) New approaches for targeting platinum-resistant ovarian cancer. Semin Cancer Biol 77:167–181CrossRefPubMed
5.
Zurück zum Zitat Armstrong DK, Alvarez RD, Bakkum-Gamez JN et al (2021) Ovarian cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 19:191–226CrossRefPubMed Armstrong DK, Alvarez RD, Bakkum-Gamez JN et al (2021) Ovarian cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 19:191–226CrossRefPubMed
6.
Zurück zum Zitat Le Saux O, Ray-Coquard I, Labidi-Galy SI (2021) Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer. Semin Cancer Biol 77:127–143CrossRefPubMed Le Saux O, Ray-Coquard I, Labidi-Galy SI (2021) Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer. Semin Cancer Biol 77:127–143CrossRefPubMed
7.
Zurück zum Zitat Baert T, Ferrero A, Sehouli J et al (2021) The systemic treatment of recurrent ovarian cancer revisited. Ann Oncol 32:710–725CrossRefPubMed Baert T, Ferrero A, Sehouli J et al (2021) The systemic treatment of recurrent ovarian cancer revisited. Ann Oncol 32:710–725CrossRefPubMed
8.
Zurück zum Zitat Konstantinopoulos PA, Waggoner S, Vidal GA et al (2019) Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma. JAMA Oncol 5:1141–1149CrossRefPubMedPubMedCentral Konstantinopoulos PA, Waggoner S, Vidal GA et al (2019) Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma. JAMA Oncol 5:1141–1149CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Konstantinopoulos PA, Cheng SC, Wahner Hendrickson AE et al (2020) Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol 21:957–968CrossRefPubMedPubMedCentral Konstantinopoulos PA, Cheng SC, Wahner Hendrickson AE et al (2020) Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol 21:957–968CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Rauh-Hain JA, Nitschmann CC, Worley MJ Jr et al (2013) Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma. Gynecol Oncol 129:63–68CrossRefPubMed Rauh-Hain JA, Nitschmann CC, Worley MJ Jr et al (2013) Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma. Gynecol Oncol 129:63–68CrossRefPubMed
11.
Zurück zum Zitat Lambin P, Leijenaar RTH, Deist TM et al (2017) Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol 14:749–762CrossRefPubMed Lambin P, Leijenaar RTH, Deist TM et al (2017) Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol 14:749–762CrossRefPubMed
12.
Zurück zum Zitat Bi WL, Hosny A, Schabath MB et al (2019) Artificial intelligence in cancer imaging: clinical challenges and applications. CA Cancer J Clin 69:127–157PubMedPubMedCentral Bi WL, Hosny A, Schabath MB et al (2019) Artificial intelligence in cancer imaging: clinical challenges and applications. CA Cancer J Clin 69:127–157PubMedPubMedCentral
13.
Zurück zum Zitat Song XL, Ren JL, Zhao D et al (2021) Radiomics derived from dynamic contrast-enhanced MRI pharmacokinetic protocol features: the value of precision diagnosis ovarian neoplasms. Eur Radiol 31:368–378CrossRefPubMed Song XL, Ren JL, Zhao D et al (2021) Radiomics derived from dynamic contrast-enhanced MRI pharmacokinetic protocol features: the value of precision diagnosis ovarian neoplasms. Eur Radiol 31:368–378CrossRefPubMed
14.
Zurück zum Zitat Li H, Zhang R, Li R et al (2021) Noninvasive prediction of residual disease for advanced high-grade serous ovarian carcinoma by MRI-based radiomic-clinical nomogram. Eur Radiol 31:7855–7864CrossRefPubMed Li H, Zhang R, Li R et al (2021) Noninvasive prediction of residual disease for advanced high-grade serous ovarian carcinoma by MRI-based radiomic-clinical nomogram. Eur Radiol 31:7855–7864CrossRefPubMed
15.
Zurück zum Zitat Zhang H, Mao Y, Chen X et al (2019) Magnetic resonance imaging radiomics in categorizing ovarian masses and predicting clinical outcome: a preliminary study. Eur Radiol 29:3358–3371CrossRefPubMed Zhang H, Mao Y, Chen X et al (2019) Magnetic resonance imaging radiomics in categorizing ovarian masses and predicting clinical outcome: a preliminary study. Eur Radiol 29:3358–3371CrossRefPubMed
16.
Zurück zum Zitat Li C, Wang H, Chen Y et al (2022) A nomogram combining MRI multisequence radiomics and clinical factors for predicting recurrence of high-grade serous ovarian carcinoma. J Oncol 2022:1716268PubMedPubMedCentral Li C, Wang H, Chen Y et al (2022) A nomogram combining MRI multisequence radiomics and clinical factors for predicting recurrence of high-grade serous ovarian carcinoma. J Oncol 2022:1716268PubMedPubMedCentral
17.
Zurück zum Zitat Lu J, Li HM, Cai SQ et al (2021) Prediction of platinum-based chemotherapy response in advanced high-grade serous ovarian cancer: ADC histogram analysis of primary tumors. Acad Radiol 28:e77–e85CrossRefPubMed Lu J, Li HM, Cai SQ et al (2021) Prediction of platinum-based chemotherapy response in advanced high-grade serous ovarian cancer: ADC histogram analysis of primary tumors. Acad Radiol 28:e77–e85CrossRefPubMed
18.
Zurück zum Zitat Veeraraghavan H, Vargas HA, Jimenez-Sanchez A et al (2020) Integrated multi-tumor radio-genomic marker of outcomes in patients with high serous ovarian carcinoma. Cancers (Basel) 12:3403CrossRefPubMed Veeraraghavan H, Vargas HA, Jimenez-Sanchez A et al (2020) Integrated multi-tumor radio-genomic marker of outcomes in patients with high serous ovarian carcinoma. Cancers (Basel) 12:3403CrossRefPubMed
19.
Zurück zum Zitat WHO Classification of Tumours Editorial Board (2020) Female genital tumours WHO classification of tumours, 5th edn. World Health Organization, Lyon, pp 32–76 WHO Classification of Tumours Editorial Board (2020) Female genital tumours WHO classification of tumours, 5th edn. World Health Organization, Lyon, pp 32–76
20.
Zurück zum Zitat Suidan RS, Ramirez PT, Sarasohn DM et al (2017) A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian cancer. Gynecol Oncol 145:27–31CrossRefPubMedPubMedCentral Suidan RS, Ramirez PT, Sarasohn DM et al (2017) A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian cancer. Gynecol Oncol 145:27–31CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Pencina MJ, D’Agostino RB Sr, D’Agostino RB Jr, Vasan RS (2008) Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 27:157–172CrossRefPubMed Pencina MJ, D’Agostino RB Sr, D’Agostino RB Jr, Vasan RS (2008) Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 27:157–172CrossRefPubMed
23.
Zurück zum Zitat Taylor EC, Irshaid L, Mathur M (2021) Multimodality imaging approach to ovarian neoplasms with pathologic correlation. Radiographics 41:289–315CrossRefPubMed Taylor EC, Irshaid L, Mathur M (2021) Multimodality imaging approach to ovarian neoplasms with pathologic correlation. Radiographics 41:289–315CrossRefPubMed
24.
Zurück zum Zitat Gadelhak B, Tawfik AM, Saleh GA et al (2019) Extended abdominopelvic MRI versus CT at the time of adnexal mass characterization for assessing radiologic peritoneal cancer index (PCI) prior to cytoreductive surgery. Abdom Radiol (NY) 44:2254–2261CrossRefPubMed Gadelhak B, Tawfik AM, Saleh GA et al (2019) Extended abdominopelvic MRI versus CT at the time of adnexal mass characterization for assessing radiologic peritoneal cancer index (PCI) prior to cytoreductive surgery. Abdom Radiol (NY) 44:2254–2261CrossRefPubMed
25.
Zurück zum Zitat Low RN, Barone RM, Lucero J (2015) Comparison of MRI and CT for predicting the peritoneal cancer index (PCI) preoperatively in patients being considered for cytoreductive surgical procedures. Ann Surg Oncol 22:1708–1715CrossRefPubMed Low RN, Barone RM, Lucero J (2015) Comparison of MRI and CT for predicting the peritoneal cancer index (PCI) preoperatively in patients being considered for cytoreductive surgical procedures. Ann Surg Oncol 22:1708–1715CrossRefPubMed
26.
Zurück zum Zitat Feng Z, Wen H, Jiang Z et al (2018) A triage strategy in advanced ovarian cancer management based on multiple predictive models for R0 resection: a prospective cohort study. J Gynecol Oncol 29:e65CrossRefPubMedPubMedCentral Feng Z, Wen H, Jiang Z et al (2018) A triage strategy in advanced ovarian cancer management based on multiple predictive models for R0 resection: a prospective cohort study. J Gynecol Oncol 29:e65CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Li HM, Gong J, Li RM et al (2021) Development of MRI-based radiomics model to predict the risk of recurrence in patients with advanced high-grade serous ovarian carcinoma. AJR Am J Roentgenol 217:664–675CrossRefPubMed Li HM, Gong J, Li RM et al (2021) Development of MRI-based radiomics model to predict the risk of recurrence in patients with advanced high-grade serous ovarian carcinoma. AJR Am J Roentgenol 217:664–675CrossRefPubMed
28.
Zurück zum Zitat Qian L, Ren J, Liu A et al (2020) MR imaging of epithelial ovarian cancer: a combined model to predict histologic subtypes. Eur Radiol 30:5815–5825CrossRefPubMed Qian L, Ren J, Liu A et al (2020) MR imaging of epithelial ovarian cancer: a combined model to predict histologic subtypes. Eur Radiol 30:5815–5825CrossRefPubMed
29.
Zurück zum Zitat Song XL, Ren JL, Yao TY et al (2021) Radiomics based on multisequence magnetic resonance imaging for the preoperative prediction of peritoneal metastasis in ovarian cancer. Eur Radiol 31:8438–8446CrossRefPubMed Song XL, Ren JL, Yao TY et al (2021) Radiomics based on multisequence magnetic resonance imaging for the preoperative prediction of peritoneal metastasis in ovarian cancer. Eur Radiol 31:8438–8446CrossRefPubMed
31.
Zurück zum Zitat Varghese BA, Cen SY, Hwang DH et al (2019) Texture analysis of imaging: what radiologists need to know. AJR Am J Roentgenol 212:520–528CrossRefPubMed Varghese BA, Cen SY, Hwang DH et al (2019) Texture analysis of imaging: what radiologists need to know. AJR Am J Roentgenol 212:520–528CrossRefPubMed
32.
Zurück zum Zitat Nie K, Shi L, Chen Q et al (2016) Rectal cancer: assessment of neoadjuvant chemoradiation outcome based on radiomics of multiparametric MRI. Clin Cancer Res 22:5256–5264CrossRefPubMed Nie K, Shi L, Chen Q et al (2016) Rectal cancer: assessment of neoadjuvant chemoradiation outcome based on radiomics of multiparametric MRI. Clin Cancer Res 22:5256–5264CrossRefPubMed
33.
Zurück zum Zitat Park H, Lim Y, KoES, et al (2018) Radiomics signature on magnetic resonance imaging: association with disease-free survival in patients with invasive breast cancer. Clin Cancer Res 24:4705–4714CrossRefPubMed Park H, Lim Y, KoES, et al (2018) Radiomics signature on magnetic resonance imaging: association with disease-free survival in patients with invasive breast cancer. Clin Cancer Res 24:4705–4714CrossRefPubMed
34.
Zurück zum Zitat Bae S, Choi YS, Ahn SS et al (2018) Radiomic MRI phenotyping of glioblastoma: improving survival prediction. Radiology 289:797–806CrossRefPubMed Bae S, Choi YS, Ahn SS et al (2018) Radiomic MRI phenotyping of glioblastoma: improving survival prediction. Radiology 289:797–806CrossRefPubMed
35.
Zurück zum Zitat Kyriazi S, Collins DJ, Messiou C et al (2011) Metastatic ovarian and primary peritoneal cancer: assessing chemotherapy response with diffusion-weighted MR imaging–value of histogram analysis of apparent diffusion coefficients. Radiology 261:182–192CrossRefPubMed Kyriazi S, Collins DJ, Messiou C et al (2011) Metastatic ovarian and primary peritoneal cancer: assessing chemotherapy response with diffusion-weighted MR imaging–value of histogram analysis of apparent diffusion coefficients. Radiology 261:182–192CrossRefPubMed
36.
Zurück zum Zitat Liu Z, Li Z, Qu J et al (2019) Radiomics of multiparametric MRI for pretreatment prediction of pathologic complete response to neoadjuvant chemotherapy in breast cancer: a multicenter study. Clin Cancer Res 25:3538–3547CrossRefPubMed Liu Z, Li Z, Qu J et al (2019) Radiomics of multiparametric MRI for pretreatment prediction of pathologic complete response to neoadjuvant chemotherapy in breast cancer: a multicenter study. Clin Cancer Res 25:3538–3547CrossRefPubMed
37.
Zurück zum Zitat Cui Y, Yang W, Ren J et al (2021) Prognostic value of multiparametric MRI-based radiomics model: potential role for chemotherapeutic benefits in locally advanced rectal cancer. Radiother Oncol 54:161–169CrossRef Cui Y, Yang W, Ren J et al (2021) Prognostic value of multiparametric MRI-based radiomics model: potential role for chemotherapeutic benefits in locally advanced rectal cancer. Radiother Oncol 54:161–169CrossRef
38.
Zurück zum Zitat Tew WP, Lacchetti C, Ellis A et al (2020) PARP Inhibitors in the management of ovarian cancer: ASCO guideline. J Clin Oncol 38:3468–3493CrossRefPubMed Tew WP, Lacchetti C, Ellis A et al (2020) PARP Inhibitors in the management of ovarian cancer: ASCO guideline. J Clin Oncol 38:3468–3493CrossRefPubMed
Metadaten
Titel
Prediction of platinum resistance for advanced high-grade serous ovarian carcinoma using MRI-based radiomics nomogram
verfasst von
Haiming Li
Songqi Cai
Lin Deng
Zebin Xiao
Qinhao Guo
Jinwei Qiang
Jing Gong
Yajia Gu
Zaiyi Liu
Publikationsdatum
30.03.2023
Verlag
Springer Berlin Heidelberg
Erschienen in
European Radiology / Ausgabe 8/2023
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-023-09552-w

Weitere Artikel der Ausgabe 8/2023

European Radiology 8/2023 Zur Ausgabe

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Klinikreform soll zehntausende Menschenleben retten

15.05.2024 Klinik aktuell Nachrichten

Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.